Thus, understanding structural features of the NPC1 and NPC2 binding domains is the first step in developing therapeutic treatments for the NPC disease as well as designing inhibitors against Ebola and Marburg viruses. This evidence concerns the gene NPC1 and nasopharyngeal carcinoma.